My Account

Change your country

Login - Register


Your Shopping Cart is empty.

Order on-line




Delphi Genetics is currently hiring
 Delphi is currently hiring two new employees: -one Scientist / QA for its

read more

Delphi Genetics will be present at Lipinov meeting on November 23 and 24
 Delphi genetics will attend the Lipinov meeting in Paris on November 23 an

read more

Delphi Genetics will be present in Munich at BIO europe
 Delphi Genetics will be present at Bio Europe 2015 in Munich on November 2

read more

Delphi Genetics will be present at BIO 2015 international convention in Philadelphia
 Delphi Genetics will be part of the Belgian delegation to BIO 2015 interna

read more


New Products

You are here : News

You may select a news to view :
< previous next >

Delphi Genetics grants licence to Sanofi Pasteur for antibiotic-free manufacturing of vaccines

15 Jun 2009

- Novel microbiological technique permits biosynthesis of proteins at higher yields and without reliance on antibiotics -

Charleroi, Belgium, June, 15, 2009 - Delphi Genetics SA (“Delphi”) today announced that the company has entered into an agreement with Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, for the manufacture of biological pharmaceuticals using Delphi’s patented StabyExpressTM technology.

StabyExpress is a new approach to stabilising the genetic machinery required to manufacture proteins, the raw materials at the heart of many modern biopharmaceuticals including vaccines, monoclonal antibodies and therapeutic proteins. Biopharmaceuticals represent a growing proportion of marketed drugs worldwide with 15 % of the worldwide pharmaceutical market.

Delphi’s StabyExpress technology improves the efficiency of protein manufacture and at a higher quality than alternative approaches.

Moreover, the technology avoids use of antibiotic resistance genes and is therefore in line with recent FDA and EMEA recommendations against the use of antibiotics in manufacturing of proteins for human and veterinary use. Many biological products currently in clinical development and licensed for sale rely on antibiotic resistance genes in the manufacturing process. The use of the StabyExpress avoids any concern regarding the use of antibiotic resistance and offers next generation biological products a more regulatory-consistent manufacturing strategy.

StabyExpress is a proprietary technology developed by Delphi Genetics. Under the agreement Sanofi Pasteur will have the non-exclusive right to use the technology for a range of vaccines it is planning to manufacture. In exchange for the licence, Delphi will receive milestone payments and royalties. No further financial details of the agreement were disclosed. 
Philippe Gabant, CEO of Delphi Genetics commented, “We have already applied the StabyExpress in a range of smaller commercial collaborations so we are pleased now that one of the world’s largest biologicals manufacturers has also recognized the importance of our technology. We look forward to further transactions of this kind with other large manufacturers of biologicals products. In addition, we have retained exclusive rights to our technology for use in specific named programmes with future strategic partners”.
In November 2008, Delphi Genetics announced a collaboration with partner Eurogentec to allow Staby technology to be included in Eurogentec's contract manufacturing offering for biological products.
Donwload the press release: English version and French version

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































< previous next >